In the first segment, Dr. Gregg Day speaks with Dr. Josep Dalmau about NMDAR antibodies in patients with first episode psychosis and the utility of criteria for autoimmune psychosis. In the second part of the podcast, Dr. Jeff Burns talks to neurologist Dr. Daniel Gibbs about his Alzheimer’s disease diagnosis and experience participating in a clinical trial for aducanumab.